Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Autor: van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M

Publikováno v: Journal of Immunotherapy (1997), 46, 197-204
van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, ' Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands ', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204 . https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams and Wilkins
Journal of Immunotherapy, 46(5), 197-204. Lippincott Williams & Wilkins

Item does not contain fulltext In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5cae1f59afc7919e206ea2bb7ce20f
https://cris.maastrichtuniversity.nl/en/publications/0bab63c2-7c57-472e-b6fd-b12fcc4f0a81

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033

Autor: Vasilis Golfinopoulos, Roger Stupp, Mohamed Ben Hassel, Jaap C. Reijneveld, Martin J B Taphoorn, A Josephine Drijver, Andreas F. Hottinger, Thierry Gorlia, Elodie Vauleon, Khê Hoang-Xuan, Daniëlle B.P. Eekers, Salvador Villà Freixa, Brigitta G. Baumert, Martin J. van den Bent, Tzahala Tzuk-Shina, Jacolien E.C. Bromberg, A. Lucas, Martin Klein

Publikováno v: Neuro-Oncology, 23(5), 803-811. Oxford University Press
Neuro-oncology, vol. 23, no. 5, pp. 803-811
Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2020, 23 (5), pp.803-811. ⟨10.1093/neuonc/noaa252⟩
Neuro-oncology, 23(5), 803-811. Oxford University Press
Neuro Oncol
Klein, M, Drijver, A J, van den Bent, M J, Bromberg, J C, Hoang-Xuan, K, Taphoorn, M J B, Reijneveld, J C, Ben Hassel, M, Vauleon, E, Eekers, D B P, Tzuk-Shina, T, Lucas, A, Freixa, S V, Golfinopoulos, V, Gorlia, T, Hottinger, A F, Stupp, R & Baumert, B G 2021, ' Memory in low-grade glioma patients treated with radiotherapy or temozolomide : a correlative analysis of EORTC study 22033-26033 ', Neuro-Oncology, vol. 23, no. 5, pp. 803-811 . https://doi.org/10.1093/neuonc/noaa252
Dipòsit Digital de la UB
Universidad de Barcelona
Neuro-Oncology, 23(5), 803-811. OXFORD UNIV PRESS INC

Background EORTC study 22033–26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f70de7d9b3083ced008800d11d981f0
https://cris.maastrichtuniversity.nl/en/publications/ce783292-0ea6-44c0-afe0-df94d7e33785

Alterations in homologous recombination repair genes in prostate cancer brain metastases

Autor: Antonio Rodriguez-Calero, John Gallon, Dilara Akhoundova, Sina Maletti, Alison Ferguson, Joanna Cyrta, Ursula Amstutz, Andrea Garofoli, Viola Paradiso, Scott A. Tomlins, Ekkehard Hewer, Vera Genitsch, Achim Fleischmann, Erik Vassella, Elisabeth J. Rushing, Rainer Grobholz, Ingeborg Fischer, Wolfram Jochum, Gieri Cathomas, Adeboye O. Osunkoya, Lukas Bubendorf, Holger Moch, George Thalmann, Charlotte K. Y. Ng, Silke Gillessen, Salvatore Piscuoglio, Mark A. Rubin

Publikováno v: Nature communications, vol. 13, no. 1, pp. 2400
Rodriguez-Calero, Antonio; Gallon, John; Akhoundova, Dilara; Maletti, Sina; Ferguson, Alison; Cyrta, Joanna; Amstutz, Ursula; Garofoli, Andrea; Paradiso, Viola; Tomlins, Scott A; Hewer, Ekkehard; Genitsch, Vera; Fleischmann, Achim; Vassella, Erik; Rushing, Elisabeth J; Grobholz, Rainer; Fischer, Ingeborg; Jochum, Wolfram; Cathomas, Gieri; Osunkoya, Adeboye O; ... (2022). Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nature Communications, 13(1), p. 2400. Springer Nature 10.1038/s41467-022-30003-5

Improved survival rates for prostate cancer through more effective therapies have also led to an increase in the diagnosis of metastases to infrequent locations such as the brain. Here we investigate the repertoire of somatic genetic alterations pres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d339acb753118a030885e55b80a56cbb
https://www.zora.uzh.ch/id/eprint/222097/

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Autor: Jean-Yves Blay, Angelica Fasolo, Palanichamy Ilankumaran, Tae Min Kim, Daniel C Cho, Jeffrey Yachnin, Filip de Vos, Martin J. van den Bent, Eduard Gasal, Albert Lai, Antje Wick, Mario Campone, Damien Pouessel, Myra E. van Linde, Alexander Stein, Jacques De Greve, Warren P. Mason, Jose A. Lopez-Martin, Anas Gazzah, Nikolas von Bubnoff, Vivek Subbiah, Gerald W. Prager, Ralf-Dieter Hofheinz, Patrick Y. Wen, Aislyn Boran, Paul Burgess

Publikováno v: The Lancet Oncology, 23(1), 53-64. Lancet Publishing Group
Wen, P Y, Stein, A, van den Bent, M, de Greve, J, Wick, A, de Vos, F Y F L, von Bubnoff, N, van Linde, M E, Lai, A, Prager, G W, Campone, M, Fasolo, A, Lopez-Martin, J A, Kim, T M, Mason, W P, Hofheinz, R-D, Blay, J-Y, Cho, D C, Gazzah, A, Pouessel, D, Yachnin, J, Boran, A, Burgess, P, Ilankumaran, P, Gasal, E & Subbiah, V 2022, ' Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial ', The Lancet Oncology, vol. 23, no. 1, pp. 53-64 . https://doi.org/10.1016/S1470-2045(21)00578-7

Background: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fad158cf6a3776974f72e32f6f4611e
https://pure.eur.nl/en/publications/6534e7d9-0966-4ffb-83ef-1054a6161e37

The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)

Autor: Cristina Barca, Claudia Foray, Sven Hermann, Ulrich Herrlinger, Isabel Remory, Damya Laoui, Michael Schäfers, Oliver M. Grauer, Bastian Zinnhardt, Andreas H. Jacobs

Publikováno v: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology

Immunomodulatory therapies have fueled interest in targeting microglial cells as part of the innate immune response after infection or injury. In this context, the colony-stimulating factor 1 (CSF-1) and its receptor (CSF-1R) have gained attention in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c71155a4e0ea75bbd889f5f0913aac5
https://www.frontiersin.org/articles/10.3389/fimmu.2021.787307/full